{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T05:20:27Z","timestamp":1779945627281,"version":"3.53.1"},"reference-count":77,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["813343"],"award-info":[{"award-number":["813343"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Non-replicating adenovirus-based vectors have been broadly used for the development of prophylactic vaccines in humans and are licensed for COVID-19 and Ebola virus disease prevention. Adenovirus-based vectored vaccines encode for one or more disease specific transgenes with the aim to induce protective immunity against the target disease. The magnitude and duration of transgene expression of adenovirus 5- based vectors (human type C) in the host are key factors influencing antigen presentation and adaptive immune responses. Here we characterize the magnitude, duration, and organ biodistribution of transgene expression after single intramuscular administration of adenovirus 26-based vector vaccines in mice and evaluate the differences with adenovirus 5-based vector vaccine to understand if this is universally applicable across serotypes. We demonstrate a correlation between peak transgene expression early after adenovirus 26-based vaccination and transgene-specific cellular and humoral immune responses for a model antigen and SARS-CoV-2 spike protein, independent of innate immune activation. Notably, the memory immune response was similar in mice immunized with adenovirus 26-based vaccine and adenovirus 5-based vaccine, despite the latter inducing a higher peak of transgene expression early after immunization and a longer duration of transgene expression. Together these results provide further insights into the mode of action of adenovirus 26-based vector vaccines.<\/jats:p>","DOI":"10.1371\/journal.pone.0299215","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T18:11:10Z","timestamp":1713291070000},"page":"e0299215","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["Peak transgene expression after intramuscular immunization of mice with adenovirus 26-based vector vaccines correlates with transgene-specific adaptive immune responses"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4067-0394","authenticated-orcid":true,"given":"Sonia","family":"Marquez-Martinez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Salisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Serroyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2822-6231","authenticated-orcid":true,"given":"Roland","family":"Zahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7081-1114","authenticated-orcid":true,"given":"Selina","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,4,16]]},"reference":[{"key":"pone.0299215.ref001","unstructured":"EMA. Zabdeno (Ad26.ZEBOV-GP, recombinant) An overview of Zabdeno and why it is authorised in the EU. 2020;EMA\/298997\/2020 (EMEA\/H\/C\/005337)."},{"key":"pone.0299215.ref002","unstructured":"EMA. Jcovden1 (COVID-19 vaccine (Ad26.COV2-S [recombinant])) An overview of Jcovden and why it is authorised in the EU. 2022;EMA\/203645\/2022(EMEA\/H\/C\/005737)."},{"issue":"5","key":"pone.0299215.ref003","article-title":"Expanding the Spectrum of Adenoviral Vectors for Cancer Therapy","volume":"12","author":"J Gao","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"2","key":"pone.0299215.ref004","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1089\/hum.2017.218","article-title":"The First Approved Gene Therapy Product for Cancer Ad-p53 (Gendicine): 12 Years in the Clinic","volume":"29","author":"WW Zhang","year":"2018","journal-title":"Hum Gene Ther"},{"issue":"4","key":"pone.0299215.ref005","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1089\/humc.2018.129","article-title":"Establishing China\u2019s National Standard for the Recombinant Adenovirus Type 5 Vector-Based Ebola Vaccine (Ad5-EBOV) Virus Titer","volume":"29","author":"Y Li","year":"2018","journal-title":"Hum Gene Ther Clin Dev"},{"issue":"3","key":"pone.0299215.ref006","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3181\/00379727-84-20714","article-title":"Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture","volume":"84","author":"WP Rowe","year":"1953","journal-title":"Proc Soc Exp Biol Med"},{"key":"pone.0299215.ref007","doi-asserted-by":"crossref","first-page":"102210","DOI":"10.1016\/j.coi.2022.102210","article-title":"Viral vector vaccines","volume":"77","author":"N McCann","year":"2022","journal-title":"Curr Opin Immunol"},{"issue":"3","key":"pone.0299215.ref008","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1172\/JCI78280","article-title":"Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling","volume":"125","author":"KM Quinn","year":"2015","journal-title":"J Clin Invest"},{"issue":"23","key":"pone.0299215.ref009","doi-asserted-by":"crossref","first-page":"12027","DOI":"10.1128\/JVI.00593-09","article-title":"Persistence of transgene expression influences CD8+ T-cell expansion and maintenance following immunization with recombinant adenovirus","volume":"83","author":"JD Finn","year":"2009","journal-title":"J Virol"},{"issue":"6","key":"pone.0299215.ref010","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1182\/blood-2007-02-062117","article-title":"Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines","volume":"110","author":"N Tatsis","year":"2007","journal-title":"Blood"},{"issue":"12","key":"pone.0299215.ref011","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1002\/eji.1830251239","article-title":"Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector","volume":"25","author":"V Juillard","year":"1995","journal-title":"Eur J Immunol"},{"issue":"1","key":"pone.0299215.ref012","doi-asserted-by":"crossref","first-page":"200","DOI":"10.4049\/jimmunol.176.1.200","article-title":"The CD8+ T cell population elicited by recombinant adenovirus displays a novel partially exhausted phenotype associated with prolonged antigen presentation that nonetheless provides long-term immunity","volume":"176","author":"TC Yang","year":"2006","journal-title":"J Immunol"},{"key":"pone.0299215.ref013","doi-asserted-by":"crossref","first-page":"16756","DOI":"10.1038\/srep16756","article-title":"Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice","volume":"5","author":"MD Dicks","year":"2015","journal-title":"Sci Rep"},{"issue":"2","key":"pone.0299215.ref014","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/sj.mt.6300024","article-title":"Type I interferon inhibits antibody responses induced by a chimpanzee adenovirus vector","volume":"15","author":"SE Hensley","year":"2007","journal-title":"Mol Ther"},{"issue":"18","key":"pone.0299215.ref015","doi-asserted-by":"crossref","first-page":"9590","DOI":"10.1128\/JVI.00740-12","article-title":"Vaccination with adenovirus serotypes 35, 26, and 48 elicits higher levels of innate cytokine responses than adenovirus serotype 5 in rhesus monkeys","volume":"86","author":"JE Teigler","year":"2012","journal-title":"J Virol"},{"issue":"10143","key":"pone.0299215.ref016","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0140-6736(18)31364-3","article-title":"Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1\/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13\u201319)","volume":"392","author":"DH Barouch","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"pone.0299215.ref017","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41541-022-00567-w","article-title":"Sequential use of Ad26-based vaccine regimens in NHP to induce immunity against different disease targets","volume":"7","author":"S Khan","year":"2022","journal-title":"NPJ Vaccines"},{"key":"pone.0299215.ref018","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41541-020-00243-x","article-title":"Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses","volume":"5","author":"R Bos","year":"2020","journal-title":"NPJ Vaccines"},{"issue":"7871","key":"pone.0299215.ref019","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41586-021-03681-2","article-title":"Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans","volume":"596","author":"G Alter","year":"2021","journal-title":"Nature"},{"key":"pone.0299215.ref020","doi-asserted-by":"crossref","first-page":"102282","DOI":"10.1016\/j.coi.2023.102282","article-title":"Cell entry and innate sensing shape adaptive immune responses to adenovirus-based vaccines","volume":"80","author":"S Marquez-Martinez","year":"2023","journal-title":"Curr Opin Immunol"},{"issue":"19","key":"pone.0299215.ref021","doi-asserted-by":"crossref","first-page":"5713","DOI":"10.7150\/jca.46463","article-title":"A tropism-transformed Oncolytic Adenovirus with Dual Capsid Modifications for enhanced Glioblastoma Therapy","volume":"11","author":"L Wang","year":"2020","journal-title":"J Cancer"},{"issue":"5","key":"pone.0299215.ref022","doi-asserted-by":"crossref","first-page":"e18205","DOI":"10.1371\/journal.pone.0018205","article-title":"Cell entry and trafficking of human adenovirus bound to blood factor X is determined by the fiber serotype and not hexon:heparan sulfate interaction","volume":"6","author":"S Corjon","year":"2011","journal-title":"PLoS One"},{"issue":"4","key":"pone.0299215.ref023","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1006\/mthe.2001.0460","article-title":"Noninvasive optical imaging of firefly luciferase reporter gene expression in skeletal muscles of living mice","volume":"4","author":"JC Wu","year":"2001","journal-title":"Mol Ther"},{"issue":"1","key":"pone.0299215.ref024","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1038\/s41598-017-03852-0","article-title":"Biodistribution and residence time of adenovector serotype 5 in normal and immunodeficient mice and rats detected with bioluminescent imaging","volume":"7","author":"Q Liu","year":"2017","journal-title":"Sci Rep"},{"issue":"6","key":"pone.0299215.ref025","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1007\/s11307-010-0440-8","article-title":"Temporal variations of skin pigmentation in C57BL\/6 mice affect optical bioluminescence quantitation","volume":"13","author":"A Curtis","year":"2011","journal-title":"Mol Imaging Biol"},{"issue":"36","key":"pone.0299215.ref026","doi-asserted-by":"crossref","first-page":"14604","DOI":"10.1073\/pnas.1209367109","article-title":"Nonviral delivery of self-amplifying RNA vaccines","volume":"109","author":"AJ Geall","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"pone.0299215.ref027","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.cell.2022.01.018","article-title":"Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination","volume":"185","author":"K Roltgen","year":"2022","journal-title":"Cell"},{"issue":"4","key":"pone.0299215.ref028","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1128\/JVI.05760-11","article-title":"Identification of adenovirus serotype 5 hexon regions that interact with scavenger receptors","volume":"86","author":"R Khare","year":"2012","journal-title":"J Virol"},{"issue":"3","key":"pone.0299215.ref029","doi-asserted-by":"crossref","first-page":"e1006914","DOI":"10.1371\/journal.ppat.1006914","article-title":"Lung macrophage scavenger receptor SR-A6 (MARCO) is an adenovirus type-specific virus entry receptor","volume":"14","author":"N Stichling","year":"2018","journal-title":"PLoS Pathog"},{"issue":"7","key":"pone.0299215.ref030","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/mt.2011.71","article-title":"Generation of a Kupffer cell-evading adenovirus for systemic and liver-directed gene transfer","volume":"19","author":"R Khare","year":"2011","journal-title":"Mol Ther"},{"issue":"22","key":"pone.0299215.ref031","doi-asserted-by":"crossref","first-page":"10274","DOI":"10.1128\/JVI.74.22.10274-10286.2000","article-title":"Dependence of adenovirus infectivity on length of the fiber shaft domain","volume":"74","author":"DM Shayakhmetov","year":"2000","journal-title":"J Virol"},{"key":"pone.0299215.ref032","article-title":"Biodistribution and immunity of adenovirus 5\/35 and modified vaccinia Ankara vector vaccines against human immunodeficiency virus 1 clade C.","author":"M Shimada","year":"2022","journal-title":"Gene Ther"},{"issue":"5304","key":"pone.0299215.ref033","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1126\/science.275.5304.1320","article-title":"Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5","volume":"275","author":"JM Bergelson","year":"1997","journal-title":"Science"},{"issue":"6","key":"pone.0299215.ref034","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.yexcr.2005.11.030","article-title":"Coxsackievirus and adenovirus receptor (CAR) is expressed in male germ cells and forms a complex with the differentiation factor JAM-C in mouse testis","volume":"312","author":"M Mirza","year":"2006","journal-title":"Exp Cell Res"},{"issue":"11","key":"pone.0299215.ref035","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/nm952","article-title":"CD46 is a cellular receptor for group B adenoviruses","volume":"9","author":"A Gaggar","year":"2003","journal-title":"Nat Med"},{"issue":"19","key":"pone.0299215.ref036","doi-asserted-by":"crossref","first-page":"10862","DOI":"10.1128\/JVI.00928-12","article-title":"Adenovirus serotype 26 utilizes CD46 as a primary cellular receptor and only transiently activates T lymphocytes following vaccination of rhesus monkeys","volume":"86","author":"H Li","year":"2012","journal-title":"J Virol"},{"issue":"2","key":"pone.0299215.ref037","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1046\/j.1365-2249.2001.01458.x","article-title":"Membrane cofactor protein (MCP; CD46) expression in transgenic mice","volume":"124","author":"C Kemper","year":"2001","journal-title":"Clin Exp Immunol"},{"issue":"9","key":"pone.0299215.ref038","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aax3567","article-title":"Human adenovirus type 26 uses sialic acid-bearing glycans as a primary cell entry receptor","volume":"5","author":"AT Baker","year":"2019","journal-title":"Sci Adv"},{"issue":"1","key":"pone.0299215.ref039","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01474-18","article-title":"alphavbeta3 Integrin Is Required for Efficient Infection of Epithelial Cells with Human Adenovirus Type 26","volume":"93","author":"D Nestic","year":"2019","journal-title":"J Virol"},{"key":"pone.0299215.ref040","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.62781","article-title":"Molecular tracking devices quantify antigen distribution and archiving in the murine lymph node","volume":"10","author":"SM Walsh","year":"2021","journal-title":"Elife"},{"issue":"6","key":"pone.0299215.ref041","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.immuni.2013.02.023","article-title":"Endocytosis and recycling of immune complexes by follicular dendritic cells enhances B cell antigen binding and activation","volume":"38","author":"BA Heesters","year":"2013","journal-title":"Immunity"},{"issue":"18","key":"pone.0299215.ref042","doi-asserted-by":"crossref","first-page":"10354","DOI":"10.1128\/JVI.00936-14","article-title":"Late endosomal trafficking of alternative serotype adenovirus vaccine vectors augments antiviral innate immunity","volume":"88","author":"JE Teigler","year":"2014","journal-title":"J Virol"},{"issue":"12","key":"pone.0299215.ref043","doi-asserted-by":"crossref","first-page":"e1008180","DOI":"10.1371\/journal.ppat.1008180","article-title":"Alpha-defensin 5 differentially modulates adenovirus vaccine vectors from different serotypes in vivo","volume":"15","author":"LJ Tartaglia","year":"2019","journal-title":"PLoS Pathog"},{"issue":"3","key":"pone.0299215.ref044","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2008.01.016","article-title":"Adenovirus serotype 5 hexon mediates liver gene transfer","volume":"132","author":"SN Waddington","year":"2008","journal-title":"Cell"},{"issue":"12","key":"pone.0299215.ref045","doi-asserted-by":"crossref","first-page":"7478","DOI":"10.1128\/JVI.79.12.7478-7491.2005","article-title":"Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity","volume":"79","author":"DM Shayakhmetov","year":"2005","journal-title":"J Virol"},{"issue":"14","key":"pone.0299215.ref046","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1073\/pnas.0711757105","article-title":"Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo","volume":"105","author":"O Kalyuzhniy","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"pone.0299215.ref047","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/15376510802312464","article-title":"Biodistribution and toxicological safety of adenovirus type 5 and type 35 vectored vaccines against human immunodeficiency virus-1 (HIV-1), Ebola, or Marburg are similar despite differing adenovirus serotype vector, manufacturer\u2019s construct, or gene inserts","volume":"5","author":"RL Sheets","year":"2008","journal-title":"J Immunotoxicol"},{"issue":"1","key":"pone.0299215.ref048","doi-asserted-by":"crossref","first-page":"e1000277","DOI":"10.1371\/journal.ppat.1000277","article-title":"The cell adhesion molecule \"CAR\" and sialic acid on human erythrocytes influence adenovirus in vivo biodistribution","volume":"5","author":"E Seiradake","year":"2009","journal-title":"PLoS Pathog"},{"issue":"3","key":"pone.0299215.ref049","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1128\/JVI.02055-12","article-title":"Comparative analysis of simian immunodeficiency virus gag-specific effector and memory CD8+ T cells induced by different adenovirus vectors","volume":"87","author":"WG Tan","year":"2013","journal-title":"J Virol"},{"issue":"9653","key":"pone.0299215.ref050","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"SP Buchbinder","year":"2008","journal-title":"Lancet"},{"issue":"10240","key":"pone.0299215.ref051","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"FC Zhu","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"pone.0299215.ref052","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1128\/jvi.69.4.2004-2015.1995","article-title":"Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses","volume":"69","author":"Y Yang","year":"1995","journal-title":"J Virol"},{"issue":"19","key":"pone.0299215.ref053","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine","volume":"384","author":"J Sadoff","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0299215.ref054","doi-asserted-by":"crossref","first-page":"313","DOI":"10.7326\/M15-0880","article-title":"Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial","volume":"164","author":"LR Baden","year":"2016","journal-title":"Ann Intern Med"},{"issue":"4","key":"pone.0299215.ref055","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41591-020-0774-y","article-title":"Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption","volume":"26","author":"DJ Colby","year":"2020","journal-title":"Nat Med"},{"issue":"6","key":"pone.0299215.ref056","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/infdis\/jiaa193","article-title":"Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged >\/ = 60 Years","volume":"222","author":"K Williams","year":"2020","journal-title":"J Infect Dis"},{"issue":"2","key":"pone.0299215.ref057","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/infdis\/jis671","article-title":"Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001)","volume":"207","author":"DH Barouch","year":"2013","journal-title":"J Infect Dis"},{"issue":"10282","key":"pone.0299215.ref058","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/S0140-6736(21)00628-0","article-title":"Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012\/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial","volume":"397","author":"KRW Emary","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"pone.0299215.ref059","doi-asserted-by":"crossref","first-page":"e0269032","DOI":"10.1371\/journal.pone.0269032","article-title":"Neutralizing antibodies levels are increased in individuals with heterologous vaccination and hybrid immunity with Ad5-nCoV in the north of Mexico","volume":"17","author":"K Cervantes-Luevano","year":"2022","journal-title":"PLoS One"},{"issue":"7830","key":"pone.0299215.ref060","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 vaccine BNT162b1 elicits human antibody and T(H)1 T cell responses","volume":"586","author":"U Sahin","year":"2020","journal-title":"Nature"},{"issue":"4","key":"pone.0299215.ref061","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1128\/CVI.00418-07","article-title":"Kinetics of recombinant adenovirus type 5, vaccinia virus, modified vaccinia ankara virus, and DNA antigen expression in vivo and the induction of memory T-lymphocyte responses","volume":"15","author":"R Geiben-Lynn","year":"2008","journal-title":"Clin Vaccine Immunol"},{"key":"pone.0299215.ref062","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3389\/fimmu.2017.00319","article-title":"The Other Function: Class II-Restricted Antigen Presentation by B Cells","volume":"8","author":"LN Adler","year":"2017","journal-title":"Front Immunol"},{"issue":"1","key":"pone.0299215.ref063","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41541-021-00301-y","article-title":"Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease","volume":"6","author":"JEM van der Lubbe","year":"2021","journal-title":"NPJ Vaccines"},{"issue":"1","key":"pone.0299215.ref064","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1038\/s41467-023-37715-2","article-title":"Booster with Ad26.COV2.S or Omicron-adapted vaccine enhanced immunity and efficacy against SARS-CoV-2 Omicron in macaques","volume":"14","author":"L Solforosi","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"pone.0299215.ref065","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41541-020-00261-9","article-title":"Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate","volume":"5","author":"R Roozendaal","year":"2020","journal-title":"NPJ Vaccines"},{"issue":"32","key":"pone.0299215.ref066","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","article-title":"Evidence for antibody as a protective correlate for COVID-19 vaccines","volume":"39","author":"KA Earle","year":"2021","journal-title":"Vaccine"},{"issue":"2","key":"pone.0299215.ref067","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3201\/eid2902.221422","article-title":"Correlates of Protection, Thresholds of Protection, and Immunobridging among Persons with SARS-CoV-2 Infection","volume":"29","author":"DS Khoury","year":"2023","journal-title":"Emerg Infect Dis"},{"issue":"20","key":"pone.0299215.ref068","doi-asserted-by":"crossref","first-page":"10383","DOI":"10.1128\/JVI.01653-15","article-title":"Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity","volume":"89","author":"JK Hu","year":"2015","journal-title":"J Virol"},{"issue":"43","key":"pone.0299215.ref069","first-page":"E6639","article-title":"Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination","volume":"113","author":"HH Tam","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"33","key":"pone.0299215.ref070","doi-asserted-by":"crossref","first-page":"16473","DOI":"10.1073\/pnas.1902179116","article-title":"Enhancing humoral immunity via sustained-release implantable microneedle patch vaccination","volume":"116","author":"AV Boopathy","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"pone.0299215.ref071","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/ijc.31166","article-title":"Adenovirus vector-based prime-boost vaccination via heterologous routes induces cervicovaginal CD8(+) T cell responses against HPV16 oncoproteins","volume":"142","author":"N Cuburu","year":"2018","journal-title":"Int J Cancer"},{"issue":"2","key":"pone.0299215.ref072","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/ijc.30679","article-title":"Development of a replication-deficient adenoviral vector-based vaccine candidate for the interception of HPV16- and HPV18-induced infections and disease","volume":"141","author":"S Khan","year":"2017","journal-title":"Int J Cancer"},{"issue":"1","key":"pone.0299215.ref073","first-page":"115","article-title":"The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12","volume":"36","author":"JV Maizel","year":"1968","journal-title":"Virology"},{"issue":"2","key":"pone.0299215.ref074","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1089\/hum.1996.7.2-215","article-title":"Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors","volume":"7","author":"FJ Fallaux","year":"1996","journal-title":"Hum Gene Ther"},{"issue":"1","key":"pone.0299215.ref075","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1099\/0022-1317-36-1-59","article-title":"Characteristics of a human cell line transformed by DNA from human adenovirus type 5","volume":"36","author":"FL Graham","year":"1977","journal-title":"J Gen Virol"},{"issue":"3","key":"pone.0299215.ref076","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/gt.2008.177","article-title":"Identification of the murine firefly luciferase-specific CD8 T-cell epitopes","volume":"16","author":"MP Limberis","year":"2009","journal-title":"Gene Ther"},{"issue":"1","key":"pone.0299215.ref077","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41541-023-00633-x","article-title":"Booster vaccination with Ad26.COV2.S or an Omicron-adapted vaccine in pre-immune hamsters protects against Omicron BA.2","volume":"8","author":"M Swart","year":"2023","journal-title":"NPJ Vaccines"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0299215","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T18:11:46Z","timestamp":1713291106000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0299215"}},"subtitle":[],"editor":[{"given":"Chen","family":"Ling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,4,16]]},"references-count":77,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0299215","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,16]]}}}